EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

GLP-1 receptor agonists are a transformative prehabilitation tool for weight loss in obese patients undergoing elective hernia repair

Graham J Spurzem iD, Ryan C Broderick, Patricia Ruiz-Cota, Hannah M Hollandsworth, Bryan J Sandler, Santiago Horgan, Eduardo Grunvald, Garth R Jacobsen

Surgical Endoscopy · 2025

DOI: 10.1007/s00464-024-11308-6 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Surgical Endoscopy, 2025. Verfasst von Graham J Spurzem und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Division of Minimally Invasive Surgery, University of California San Diego, San Diego, CA, USA. gspurzem@health.ucsd.edu. Hauptthemen laut MEDLINE: Weight Loss, Herniorrhaphy, Obesity, Glucagon-Like Peptide-1 Receptor Agonists. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Obesity is an independent risk factor for complications after abdominal hernia repair. Glucagon-like-peptide-1 (GLP-1) receptor agonists are gaining popularity as pharmacologic weight loss adjuncts and may help patients reach weight loss goals for surgery. We examine our early experience utilizing GLP-1 agonists versus lifestyle modifications alone to achieve weight loss in patients before elective hernia repair.

Methods

This single-center, retrospective review identified obese patients who underwent elective hernia repair from 2014 to 2023. Patients were asked to achieve a BMI ≤ 33 kg/m 2 before surgery. Patients who lost weight with GLP-1 therapy in addition to lifestyle changes were compared to a control cohort that achieved similar preoperative weight loss without GLP-1 therapy. Primary outcome was mean time from GLP-1 agonist initiation and initial surgery clinic visit to surgery. Secondary outcomes were 30-day morbidity, mortality, and reoperation rates, and hernia recurrence.

Results

Forty-six patients with ventral/incisional, flank, umbilical, parastomal, inguinal, and hiatal hernias were identified (GLP-1 N = 24, control N = 22). 81.8% ( N = 18) of controls had a ventral/incisional hernia, compared to 45.8% ( N = 11) of GLP-1 patients ( p = 0.03). Mean BMI at GLP-1 agonist initiation was similar to mean BMI at initial clinic visit for controls (38.1 ± 4.9 vs 38.2 ± 2.7 kg/m 2 , p = 0.66). Preoperative mean percentage total weight loss (14.9 ± 7.5 vs 12.4 ± 6.9 kg, p = 0.39) and mean BMI reduction (6.0 ± 3.8 vs 4.9 ± 2.3 kg/m 2 , p = 0.43) were similar between groups. The mean time from GLP-1 agonist initiation to surgery was significantly shorter than initial clinic visit to surgery for controls (6.3 ± 4.0 vs 14.7 ± 17.6 months, p = 0.03). There was no statistically significant difference in time from initial clinic visit to surgery between groups (7.6 ± 4.4 vs 14.7 ± 17.6 months, p = 0.06). There was no significant difference in 30-day morbidity between groups (8.3 vs 27.3%, p = 0.13).

Conclusion

GLP-1 agonists accelerate preoperative weight loss for obese hernia patients without negatively impacting postoperative outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Weight LossHerniorrhaphyObesityGlucagon-Like Peptide-1 Receptor AgonistsHumansFemaleMaleRetrospective StudiesMiddle AgedElective Surgical ProceduresAgedAdultExenatideHernia, AbdominalBody Mass Index

Stichwörter der Autor:innen

GLP-1Glucagon-like peptide 1HerniaObesityPrehabilitationWeight loss

Substanzen

ExenatideGlucagon-Like Peptide-1 Receptor Agonists

Autor:innen und Institutionen

  • Department of Surgery, Division of Minimally Invasive Surgery, University of California San Diego, San Diego, CA, USA. gspurzem@health.ucsd.edu.
  • Department of Surgery, Division of Minimally Invasive Surgery, University of California San Diego, San Diego, CA, USA.
  • Division of General Internal Medicine, Bariatric and Metabolic Institute, University of California San Diego, San Diego, CA, USA.

ORCID-Profile: Graham J Spurzem

Zitieren

APA

Spurzem, G. J., Broderick, R. C., Ruiz-Cota, P., Hollandsworth, H. M., Sandler, B. J., Horgan, S., Grunvald, E., & Jacobsen, G. R. (2025). GLP-1 receptor agonists are a transformative prehabilitation tool for weight loss in obese patients undergoing elective hernia repair. Surgical Endoscopy. https://doi.org/10.1007/s00464-024-11308-6

Vancouver

Spurzem GJ, Broderick RC, Ruiz-Cota P, Hollandsworth HM, Sandler BJ, Horgan S, et al. GLP-1 receptor agonists are a transformative prehabilitation tool for weight loss in obese patients undergoing elective hernia repair. Surgical Endoscopy. 2025. doi:10.1007/s00464-024-11308-6

BibTeX
@article{Spurzem2025,
  author = {Spurzem, Graham J and Broderick, Ryan C and Ruiz-Cota, Patricia and Hollandsworth, Hannah M and Sandler, Bryan J and Horgan, Santiago and Grunvald, Eduardo and Jacobsen, Garth R},
  title = {GLP-1 receptor agonists are a transformative prehabilitation tool for weight loss in obese patients undergoing elective hernia repair},
  journal = {Surgical Endoscopy},
  year = {2025},
  doi = {10.1007/s00464-024-11308-6}
}
Kostenlos starten →